German Guidelines Seek To Boost Biosimilar Uptake
Prescribers In Germany Are Asked To Factor Economic Benefits Of Biosimilars
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.
You may also be interested in...
The G-BA has explained in more detail the procedures for mandating post-launch evidence generation under new legislation introduced in 2019.
A German bill aims to cut spending on biologics, but new revisions mean that measures on biosimilar substitution are likely to be delayed by three years.
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.